The cytotoxic T-lymphocyte response against a poorly immunogenic mammary adenocarcinoma is focused on a single immunodominant class I epitope derived from the gp70 Env product of an endogenous retrovirus

Cancer Research

Volumn 63, Issue 9, 2003, Pages 2158-2163

  Rosato, Antonio ^a   Dalla Santa, Silvia ^a   Zoso, Alessia ^a   Giacomelli, Sofia ^a   Milan, Gabriella ^a   Macino, Beatrice ^a   Tosello, Valeria ^a   Dellabona, Paolo ^b   Lollini, Pier Luigi ^c   De Giovanni, Carla ^c   Zanovello, Paola ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIGEN; CD8 ANTIGEN; EPITOPE; GAMMA INTERFERON; INTERLEUKIN 4; PEPTIDE; PROTEIN; PROTEIN GP 70; TETRAMER; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGENICITY; ARTICLE; ASSAY; BREAST ADENOCARCINOMA; CELL STIMULATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GENETIC CODE; GENETIC ENGINEERING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOGENICITY; IN VIVO STUDY; LYSIS; MIXED LEUKOCYTE CULTURE; MOUSE; MURINE LEUKEMIA VIRUS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RETROVIRUS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLEEN CELL; STAINING; TUMOR CELL CULTURE; TUMOR CELL LINE; TUMOR GROWTH; TUMOR REGRESSION;

ADENOCARCINOMA; ANIMALS; ANTIGENS, CD80; ANTIGENS, NEOPLASM; FEMALE; IMMUNODOMINANT EPITOPES; INTERFERON TYPE II; INTERFERON-ALPHA; INTERLEUKIN-4; LYMPHOCYTE ACTIVATION; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; RETROVIRIDAE; RETROVIRIDAE PROTEINS, ONCOGENIC; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION; VIRAL ENVELOPE PROTEINS;

EID: 0037728812     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Forni, G., and Boggio, K. Cytokine gene-engineered vaccines. Curr. Opin. Mol. Ther., 1: 34-38., 1999.
2. Musiani, P., Modesti, A., Giovarelli, M., Cavallo, F., Colombo, M. P., Lollini, P. L., and Fomi, G. Cytokines, tumour-cell death and immunogenicity: a question of choice. Immunol. Today, 18: 32-36, 1997.
3. Nanni, P., Fomi, G., and Lollini, P. L. Cytokine gene therapy: hopes and pitfalls. Ann. Oncol., 10: 261-266, 1999.
4. Lollini, P. L., Bosco, M. C., Cavallo, F., De Giovanni, C., Giovarelli, M., Landuzzi, L., Musiani, P., Modesti, A., Nicoletti, G., Palmieri, G., et al. Inhibition of tumor growth and enhancement of metastasis after transfection of the gamma-interferon gene. Int. J. Cancer, 55: 320-329, 1993.
5. Allione, A., Consalvo, M., Nanni, P., Lollini, P. L., Cavallo, F., Giovarelli, M., Fomi, M., Gulino, A., Colombo, M. P., Dellabona, P., et al. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor alpha, granulocyte-macrophage colony-stimulating factor, and gamma-interferon gene or admixed with conventional adjuvants. Cancer Res., 54: 6022-6026, 1994.
6. Ferrantini, M., Giovarelli, M., Modesti, A., Musiani, P., Modica, A., Venditti, M., Peretti, E., Lollini, P. L., Nanni, P., Fomi, G., et al. IFN-α 1 gene expression into a metastatic murine adenocarcinoma (TS/A) results in CD8+ T cell-mediated tumor rejection and development of antitumor immunity. Comparative studies with IFN-γ producing TS/A cells. J. Immunol., 153: 4604-4615, 1994.
7. Cavallo, F., Martin-Fontecha, A., Bellone, M., Heltai, S., Gatti, E., Tomaghi, P., Freschi, M., Forni, G., Dellabona, P., and Casorati, G. Co-expression of B7-1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response. Eur. J. Immunol., 25: 1154-1162, 1995.
8. Zitvogel, L., Robbins, P. D., Storkus, W. J., Clarke, M. R., Maeurer, M. J., Campbell, R. L., Davis, C. G., Tahara, H., Schreiber, R. D., and Lotze, M. T. Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors. Eur. J. Immunol., 26: 1335-1341, 1996.
9. Cayeux, S., Richter, G., Noffz, G., Dorken, B., and Blankenstein, T. Influence of gene-modified (IL-7, IL-4, and B7) tumor cell vaccines on tumor antigen presentation. J. Immunol., 158: 2834-2841, 1997.
10. Mackey, M. F., Gunn, J. R., Ting, P. P., Kikutani, H., Dranoff, G., Noelle, R. J., and Barth, R. J., Jr. Protective immunity induced by tumor vaccines requires interaction between CD40 and its ligand, CD154. Cancer Res., 57: 2569-2574, 1997.
11. Puisieux, I., Odin, L., Poujol, D., Moingeon, P., Tartaglia, J., Cox, W., and Favrot, M. Canarypox virus-mediated interleukin 12 gene transfer into murine mammary adenocarcinoma induces tumor suppression and long-term antitumoral immunity. Hum. Gene Ther., 9: 2481-2492, 1998.
12. Oshikawa, K., Shi, F., Rakhmilevich, A. L., Sondel, P. M., Mahvi, D. M., and Yang, N. S. Synergistic inhibition of tumor growth in a murine mammary adenocarcinoma model by combinational gene therapy using IL-12, pro-IL-18, and IL-1β converting enzyme cDNA. Proc. Natl. Acad. Sci. USA, 96: 13351-13356, 1999.
13. Douin-Echinard, V., Bornes, S., Rochaix, P., Tilkin, A. F., Peron, J. M., Bonnet, J., Favre, G., and Couderc, B. The expression of CD70 and CD80 by gene-modified tumor cells induces an antitumor response depending on the MHC status. Cancer Gene Ther., 7: 1543-1556, 2000.
14. Pericle, F., Giovarelli, M., Colombo, M. P., Ferrari, G., Musiani, P., Modesti, A., Cavallo, F., Di Pierro, F., Novelli, F., and Fomi, G. An efficient Th2-type memory follows CD8+ lymphocyte-driven and eosinophil-mediated rejection of a spontaneous mouse mammary adenocarcinoma engineered to release IL-4. J. Immunol., 153: 5659-5673, 1994.
15. Milan, G., Zambon, A., Cavinato, M., Zanovello, P., Rosato, A., and Collavo, D. Dissecting the immune response to Moloney murine sarcoma/leukemia virus-induced tumors by means of a DNA vaccination approach. J. Virol., 73: 2280-2287, 1999.
16. Iezzi, G., Rivolta, L., Ronchetti, A., Martin-Fontecha, A., Rosato, A., Protti, M. P., Sabbadini, M. G., and Bellone, M. The immunogenicity of experimental tumors is strongly biased by the expression of dominant viral cytotoxic T-lymphocyte epitopes. Cancer Res., 57: 2564-2568, 1997.
17. Yang, J. C., and Perry-Lalley, D. The envelope protein of an endogenous murine retrovirus is a tumor-associated T-cell antigen for multiple murine tumors. J. Immunother., 23: 177-183, 2000.
18. Ryan, M. H., Bristol, J. A., McDuffie, E., and Abrams, S. I. Regression of extensive pulmonary metastases in mice by adoptive transfer of antigen-specific CD8(+) CTL reactive against tumor cells expressing a naturally occurring rejection epitope. J. Immunol., 167: 4286-4292, 2001.
19. Huang, A. Y., Gulden, P. H., Woods, A. S., Thomas, M. C., Tong, C. D., Wang, W., Engelhard, V. H., Pasternack, G., Cotter, R., Hunt, D., Pardoll, D. M., and Jaffee, E. M. The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Proc. Natl. Acad. Sci. USA, 93: 9730-9735, 1996.
20. Nanni, P., de Giovanni, C., Lollini, P. L., Nicoletti, G., and Prodi, G. TS/A: a new metastasizing cell line from a BALB/c spontaneous mammary adenocarcinoma. Clin. Exp. Metastasis, 1: 373-380, 1983.
21. Rosato, A., Zambon, A., Milan, G., Ciminale, V., D'Agostino, D. M., Macino, B., Zanovello, P., and Collavo, D. CTL response and protection against P815 tumor challenge in mice immunized with DNA expressing the tumor-specific antigen P815A. Hum. Gene Ther., 8: 1451-1458, 1997.
22. Workman, P., Balmain, A., Hickman, J. A., McNally, N. J., Rohas, A. M., Mitchison, N. A., Pierrepoint, C. G., Raymond, R., Rowlatt, C., Stephens, T. C., et al. UKCCCR guidelines for the welfare of animals in experimental neoplasia. Lab. Anim., 22: 195-201, 1988.
23. Rosato, A., Milan, G., Collavo, D., and Zanovello, P. DNA-based vaccination against tumors expressing the P1A antigen. Methods, 19: 187-190, 1999.
24. Garboczi, D. N., Hung, D. T., and Wiley, D. C. HLA-A2-peptide complexes: refolding and crystallization of molecules expressed in Escherichia coli and complexed with single antigenic peptides. Proc. Natl. Acad. Sci. USA, 89: 3429-3433, 1992.
25. Lee, K. H., Wang, E., Nielsen, M. B., Wunderlich, J., Migueles, S., Connors, M., Steinberg, S. M., Rosenberg, S. A., and Marincola, F. M. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J. Immunol., 163: 6292-6300, 1999.
26. Kershaw, M. H., Hsu, C., Mondesire, W., Parker, L. L., Wang, G., Overwijk, W. W., Lapointe, R., Yang, J. C., Wang, R. F., Restifo, N. P., and Hwu, P. Immunization against endogenous retroviral tumor-associated antigens. Cancer Res., 61: 7920-7924, 2001.
27. Rovero, S., Amici, A., Carlo, E. D., Bei, R., Nanni, P., Quaglino, E., Porcedda, P., Boggio, K., Smorlesi, A., Lollini, P. L., Landuzzi, L., Colombo, M. P., Giovarelli, M., Musiani, P., and Forni, G. DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J. Immunol., 165: 5133-5142, 2000.
28. Beatty, G. L., and Paterson, Y. IFN-γ can promote tumor evasion of the immune system in vivo by down-regulating cellular levels of an endogenous tumor antigen. J. Immunol., 165: 5502-5508, 2000.
29. Zeh, H. J., 3rd, Perry-Lalley, D., Dudley, M. E., Rosenberg, S. A., and Yang, J. C. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J. Immunol., 162: 989-994, 1999.
30. Stoye, J. P. Endogenous retroviruses: still active after all these years? Curr. Biol., 11: R914-R916, 2001.
31. Griffiths, D. J. Endogenous retroviruses in the human genome sequence. Genome Biol., 2: 1017.1-1017.5, 2001.
32. Perl, A. Endogenous retroviruses in pathogenesis of autoimmunity. J. Rheumatol., 28: 461-464, 2001.
33. Portis, J. L. Perspectives on the role of endogenous human retroviruses in autoimmune diseases. Virology, 296: 1-5, 2002.
34. Armbruester, V., Sauter, M., Krautkraemer, E., Meese, E., Kleiman, A., Best, B., Roemer, K., and Mueller-Lantzsch, N. A novel gene from the human endogenous retrovirus k expressed in transformed cells. Clin. Cancer Res., 8: 1800-1807, 2002.
35. Moshier, J. A., Luk, G. D., and Huang, R. C. mRNA from human colon tumor and mucosa related to the pol gene of an endogenous A-type retrovirus. Biochem. Biophys. Res. Commun., 139: 1071-1077, 1986.
36. Sauter, M., Schommer, S., Kremmer, E., Remberger, K., Dolken, G., Lemm, I., Buck, M., Best, B., Neumann-Haefelin, D., and Mueller-Lantzsch, N. Human endogenous retrovirus K10: expression of Gag protein and detection of antibodies in patients with seminomas. J. Virol., 69: 414-421, 1995.
37. Wahlstrom, T., Suni, J., Nieminen, P., Narvanen, A., Lehtonen, T., and Vaheri, A. Renal cell adenocarcinoma and retrovirus p30-related antigen excreted to urine. Lab. Investig., 53: 464-469, 1985.
38. Moyret, C. F., Bernard, D. J., Maurizis, J. C., Chollet, P., and Plagne, R. Detection of reverse transcriptase activity in human breast tumors. Anticancer Res., 8: 1279-1283, 1988.
39. Wang-Johanning, F., Frost, A. R., Johanning, G. L., Khazaeli, M. B., LoBuglio, A. F., Shaw, D. R., and Strong, T. V. Expression of human endogenous retrovirus k envelope transcripts in human breast cancer. Clin. Cancer Res., 7: 1553-1560, 2001.
40. Schiavetti, F., Thonnard, J., Colau, D., Boon, T., and Coulie, P. G. A human endogenous retroviral sequence encoding an antigen recognized on melanoma by cytolytic T lymphocytes. Cancer Res., 62: 5510-5516, 2002.